Diabetes Care. 2013;36(10):3169-3176. During the baseline SHC, mean GFR was similar in type 2 diabetic (127 ± 34 mL/min) and healthy (128 ± 36 mL/min) subjects. During the repeat SHC after 7 days of ...
A new study published in the journal of Frontiers in Endocrinology showed that patients with diabetic kidney disease (DKD) benefit greatly from Sodium-glucose cotransporter-2 (SGLT2) ...
Data taken from [22,23]. placebo Fasting serum glucose (%):/DP100 mg: −21.8/DP25 mg: −13.3/DP5 mg−11.7 Significant improvement in oral glucose tolerance test compared with placebo. Urinary glucose ...
SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...
Dapagliflozin propanediol is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. By reducing glucose reabsorption in the ...
1d
Normally, the glucose that is filtered from the blood by the kidneys is almost entirely reabsorbed.
*Another potential reason is the timing of the urine sample. “Perhaps the urine sample was taken some time after a short-lived increase in blood sugar, such as after a large meal, and the sugar was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results